These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 16678077

  • 1. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [Abstract] [Full Text] [Related]

  • 2. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF, Loftus EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ.
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [Abstract] [Full Text] [Related]

  • 3. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A, Sandborn WJ.
    Am J Gastroenterol; 2012 Sep; 107(9):1409-22. PubMed ID: 22890223
    [Abstract] [Full Text] [Related]

  • 4. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease.
    Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ.
    Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351
    [Abstract] [Full Text] [Related]

  • 5. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.
    Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ.
    Am J Gastroenterol; 2014 Feb; 109(2):212-23. PubMed ID: 24394749
    [Abstract] [Full Text] [Related]

  • 6. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD.
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [Abstract] [Full Text] [Related]

  • 7. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
    Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.
    Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127
    [Abstract] [Full Text] [Related]

  • 8. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B.
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [Abstract] [Full Text] [Related]

  • 9. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.
    N Engl J Med; 2003 Feb 13; 348(7):601-8. PubMed ID: 12584368
    [Abstract] [Full Text] [Related]

  • 10. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
    Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
    Gastroenterology; 2006 Apr 13; 130(4):1054-61. PubMed ID: 16618399
    [Abstract] [Full Text] [Related]

  • 11. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
    Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.
    Br J Dermatol; 2006 Jul 13; 155(1):160-9. PubMed ID: 16792769
    [Abstract] [Full Text] [Related]

  • 12. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P.
    Gut; 2009 Apr 13; 58(4):501-8. PubMed ID: 18832524
    [Abstract] [Full Text] [Related]

  • 13. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
    Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Apr 01; 19(7):749-54. PubMed ID: 15043515
    [Abstract] [Full Text] [Related]

  • 14. Mortality and cause of death in Japanese patients with Crohn's disease.
    Uno H, Yao T, Matsui T, Sakurai T, Iida M, Matsumoto T, Aoyagi K, Fuchigami T.
    Dis Colon Rectum; 2003 Oct 01; 46(10 Suppl):S15-21. PubMed ID: 14530654
    [Abstract] [Full Text] [Related]

  • 15. Safety of infliximab in 10 years of clinical practice.
    O'Donnell S, Murphy S, Anwar MM, O'Sullivan M, Breslin N, O'Connor HJ, Ryan BM, O'Morain CA.
    Eur J Gastroenterol Hepatol; 2011 Jul 01; 23(7):603-6. PubMed ID: 21602689
    [Abstract] [Full Text] [Related]

  • 16. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence.
    Ferrante M, de Hertogh G, Hlavaty T, D'Haens G, Penninckx F, D'Hoore A, Vermeire S, Rutgeerts P, Geboes K, van Assche G.
    Gastroenterology; 2006 May 01; 130(6):1595-606. PubMed ID: 16697723
    [Abstract] [Full Text] [Related]

  • 17. Risks and benefits of infliximab for the treatment of Crohn's disease.
    Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE.
    Clin Gastroenterol Hepatol; 2006 Aug 01; 4(8):1017-24; quiz 976. PubMed ID: 16843733
    [Abstract] [Full Text] [Related]

  • 18. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P, Danish Crohn Colitis Database.
    Clin Gastroenterol Hepatol; 2008 Nov 01; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [Abstract] [Full Text] [Related]

  • 19. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms.
    Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J.
    J Pediatr Gastroenterol Nutr; 2009 Feb 01; 48(2):168-74. PubMed ID: 19179878
    [Abstract] [Full Text] [Related]

  • 20. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA.
    Aliment Pharmacol Ther; 2010 Mar 01; 31(5):553-60. PubMed ID: 20002026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.